PRTG
SNDX icon

Post Resch Tallon Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Post Resch Tallon Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Hold
12,500
– – 0.19% 94
2026
Q1 		$302K Sell
12,500
-10,300
-45% -$224K 0.24% 75
2025
Q4 		$479K Sell
22,800
-3,000
-12% -$52.3K 0.4% 48
2025
Q3 		$397K Buy
+25,800
New +$338K 0.35% 54

Other funds holding SNDX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $165M AUM 27.01% 1-Year Est. Return

Post Resch Tallon Group's SNDX Position: Q2 2026 in Review

Post Resch Tallon Group held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 12,500 shares worth $273K. The position accounts for 0.19% of the portfolio, ranked #94.

Post Resch Tallon Group first reported a position in SNDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $479K in Q4 2025. 15 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Post Resch Tallon Group held 12,500 shares of Syndax Pharmaceuticals worth $273K as of Q2 2026.
  • Post Resch Tallon Group left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.19% of Post Resch Tallon Group's portfolio in Q2 2026, its #94 holding.
  • Post Resch Tallon Group first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Post Resch Tallon Group's Syndax Pharmaceuticals position peaked at $479K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Post Resch Tallon Group's 13F filing for Q2 2026, filed 7 Jul 2026.